Moderna (MRNA) to Join Nasdaq-100 as Warner Bros. Discovery Exit
Nasdaq announced Moderna (MRNA) will join the Nasdaq-100 Index, replacing Warner Bros. Discovery (WBD) on October 9. Moderna's P/S ratio is 33.22, well above its historical median of 8.41, reflecting high growth expectations despite its unprofitability. The company's GF Score is 56, indicating moderate fundamental quality. Insider activity shows no purchases and $64.6M in sales over the past year. Moderna's market cap is approximately $75.43B.
How this was made
The 30-second read
Why it matters
The change signals market recognition of Moderna's growth trajectory but also highlights valuation concerns.
Market read
Index rebalancing can create short‑term buying pressure for the added stock and selling pressure for the removed one.
What to watch
High valuation (P/S 33x) and ongoing losses may limit upside despite the index boost.
Background
Nasdaq announced the upcoming reconstitution of the Nasdaq‑100, adding Moderna (MRNA) and removing Warner Bros. Discovery (WBD).
Ticker impact
Moderna is being added to the Nasdaq-100, replacing Warner Bros. Discovery, a first‑report index change that can affect its share demand.
likely modest upside as index funds rebalance and new investors add exposure
Nasdaq-100 additions historically generate short‑term buying pressure; no countervailing news is present.
Market effects
Biotech and broader healthcare ETFs may see slight inflows as a marquee biotech joins a major index.
U.S. equity markets may see a small uptick in Nasdaq‑related indices.
Global passive fund managers tracking the Nasdaq‑100 will adjust holdings, modestly affecting worldwide demand for MRNA shares.
Counterpoint
If the index addition is already priced in, the stock could face short‑term profit‑taking after the initial buying wave.
Key entities
- companyModerna Inc.
Biotech firm joining the Nasdaq‑100.
- companyWarner Bros. Discovery
Company being removed from the Nasdaq‑100.
